Celldex Therapeutics (CLDX) Research & Development (2010 - 2026)

Celldex Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $73.0 million for Q1 2026.

• On a quarterly basis, Research & Development rose 38.75% year-over-year to $73.0 million in Q1 2026; TTM through Mar 2026 was $265.5 million, a 43.88% increase from a year earlier, with the FY2025 full-year figure at $245.1 million, up 49.85% from the prior year.
• Research & Development eased to $73.0 million in Q1 2026 per CLDX's latest filing, from $75.3 million in the prior quarter.
• Across five years, Research & Development topped out at $75.3 million in Q4 2025 and bottomed at $17.1 million in Q1 2022.
• The 5-year median for Research & Development is $34.5 million (2023), against an average of $40.1 million.
• Across the five-year window, Research & Development surged 67.78% in 2022 and advanced 18.15% in 2024, its largest moves.
• Year by year, Research & Development stood at $22.9 million in 2022, then soared by 32.87% to $30.4 million in 2023, then soared by 54.27% to $46.9 million in 2024, then jumped by 60.49% to $75.3 million in 2025, then declined by 3.1% to $73.0 million in 2026.
• Per Business Quant, the three latest CLDX Research & Development figures stand at $73.0 million (Q1 2026), $75.3 million (Q4 2025), and $62.9 million (Q3 2025).